EU PHARMACEUTICALS TB500

EU PHARMACEUTICALS(5MG/2ML VIAL)

Thymosin Beta 4, or TB-500, is a synthetic version of a naturally occurring 43-amino acid peptide present in nearly all human and animal cells studied.

A 2010 study in the Annals of the New York Academy of Sciences supported TB500’s potential for cardiac muscle repair following injury, eg, after myocardial infarction (heart attack).  Recognizing the limitations of stem cell therapy for this application, TB500 was found to inhibit myocardial cell death, stimulate blood vessel growth, and activate cardiac processes that encouraged the heart to heal following injury.  The investigation showed that TB500 may be the first agent which can actively recover injured cardiac muscle following heart attack.  This is further supported with prior mouse studies in 2004 showing cardiomyocyte migration, survival and repair of myocardial damage.  [1] [2]

Filamentous actin (F-actin, or actin) forms polymers that thicken sputum, adversely affecting cystic fibrosis patients.  TB500 was studied in a population of CF patients, showing a dose- and time-dependent decrease in cohesivity of sputum after administration of TB500 when combined with dornase alfa.  The combination therapy showed a 71% improvement in mucociliary transport of mucus, and a 44% improvement in cough transport of mucus.  [3

TB500 is known to stimulate myoblasts and myocytes (muscle generating cells).  Mitochondrial RNA levels of TB500 have been shown to increase following muscle injury, helping to regenerate muscle fibers and address inflammation in the injured location.  The data support muscle injury causing increased local production of TB500, promoting migration of incoming myoblasts to accelerate skeletal muscle regeneration.  [4]

TB-500 is a synthetic version of the naturally occurring peptide present in virtually all human and animal cells, Thymosin Beta 4 (Tß4). It is a first-in-class peptide candidate that promotes the following*: Endothelial (blood vessels) cell differentiation Angiogenesis (growth of new blood cells from pre-existing vessels) in dermal tissues Keratinocyte migration Collagen deposition; and Decreases inflammation.

TB-500 offers many benefits to the equine world in performance racing. Recent trials by some of the world’s leading trainers on their prize winning equine members of both genders, have been credited by a huge boost in their race-day results, something long desired in the racing world. These trials along with clinical trials have indicated the following benefits associated with the use of TB-500 on mares and stallions: Increase muscle growth with huge increases in endurance and strength noted Relaxed muscle spasm Improved muscle tone Increase the exchange of substance between cells Encourage tissue repair Stretches connective tissue Helps maintain flexibility Reduces inflammation of tissue in joint Enhances nutritional components in the animal Prevents the formations of adhesions and fibrous bands in muscles, tendons and ligaments. When these proven benefits are viewed in conjunction with the fact that 60% of a horse’s body weight is muscle, it is clear to see the full potential of TB500 can be reviled in by majority of the horse’s body. In a racing era that surrounds itself around gaining that competitive edge through the use of various substances, none will deliver the results that will be experienced with the use of TB-500. Perhaps the greatest selling point of the product is that it’s 100% DRUG FREE and DOES NOT SWAB. This allows the peptide to be used right throughout racing spells in both training and competition completely free of any banned substance.

TB-500 dosage and cycle duration:

Dosage depends on the purpose and severity of the injury / damage you are treating. People generally use between 4 to 8 mg of TB500 per week during the initial (loading) period of 4 to 6 weeks. Afterwards some opt to maintain the effects with a low 2 to 6 mg dose once every 2 weeks. The effects of TB-500 wear off within 2 – 3 weeks of injection.

1. TB-500 loading phase:
duration: between 4 – 6 weeks
dosage: between 4 – 8 mg of TB-500 per week
frequency of injection:2 mg per injection, between 2 – 4 times per week (depending on the total weekly dosage)

2. TB-500 maintainance phase:
duration: as long as needed
dosage: between 2 – 6 mg of TB-500 per 2 weeks
frequency of injection:2 mg per injection, between 2 – 3 times per 2 weeks (depending on the total bi-weekly dosage)